ACA Arcosa (ACA) Insider Trading, Ownership & Congress Trades
Industrials · Fabricated structural metal products · CIK 0001739445
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
233
13F, latest reported quarter
Arcosa insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Arcosa, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Aug 16, 2024.
- The trade is 10.5% of the 38,089 shares held after it.
- 1 other insider sold within 30 days.
- 233 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CLO & Asst Corp Sec. Stevenson Bryan sold about $396.1K of ACA on Aug 12, 2025; 1 other insider sold within 30 days and 233 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on May 15, 2024.
- The trade is 40.3% of the 19,769 shares held after it.
- 1 other insider sold within 30 days.
- 233 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Group President Cole Kerry S sold about $762.9K of ACA on Aug 11, 2025, the largest insider sale at the company since 2023; 1 other insider sold within 30 days and 233 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on May 15, 2024.
- The trade is 26.7% of the 16,701 shares held after it.
- No other insider sold within 30 days.
- 233 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Group President Collins Jesse E. Jr. sold about $384.2K of ACA on Jun 17, 2025, the largest insider sale at the company since 2024; 233 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on May 15, 2024.
- The trade is 33.1% of the 12,551 shares held after it.
- No other insider sold within 30 days.
- 233 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Group President Collins Jesse E. Jr. sold about $360.2K of ACA on Jun 17, 2025, the largest insider sale at the company since 2024; 233 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 20.3% of the 4,112 shares held after it.
- No other insider sold within 30 days.
- 233 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: VP Controller (PAO) Hurst Eric D sold about $74.0K of ACA on May 15, 2025; 233 funds added in the latest 13F quarter.39 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
233 funds bought in last quarter
more than 63% of Industrials
Revenue
+12.2% year over year
more than 71% of Industrials
Margin
7.2% net margin
more than 60% of Industrials
Buybacks
$17.5M repurchased, FY to 2026-06-30
below 67% of Industrials
Short interest
3.1% of the float short (float per yahoo 2026-10-26) · 1.8 days to cover · settled 2026-09-30
below 53% of Industrials
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch ACA
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+61.8%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns ACA: institutional holders (13F)
13F holdings, latest reported quarter
8,414,107 sh
$1.2B
2,817,292 sh
$409.3M
2,351,171 sh
$341.6M
2,210,245 sh
$321.1M
2,078,928 sh
$302.0M
Congress trades in ACA
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
ACA planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
ACA mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Corgi High Voltage Grid Equipment ETF
$549.2K position · as of 2026-06-30
4.5%
Nomura Energy Transition ETF
$511.1K position · as of 2026-06-30
4.5%
Royce Premier Fund
$43.4M position · as of 2026-06-30
3.8%
TCW Relative Value Mid Cap Fund
$5.1M position · as of 2026-07-31
3.1%
State Street(R) SPDR(R) S&P Kensho Clean Power ETF
$7.5M position · as of 2026-06-30
3.0%
GMO Domestic Resilience ETF
$1.0M position · as of 2026-05-31
2.8%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Mr. Carrillo
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$8.1M
$10.6M
$2.3M
+96%
+139%
2024
$7.3M
$13.9M
$1.8M
+78%
+117%
2023
$6.5M
$16.8M
$2.2M
+52%
+74%
2022
$6.3M
$8.6M
$1.5M
+0%
+15%
2021
$5.6M
$6.1M
$1.0M
-4%
+44%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 233 funds added last quarter. Each figure is a federal filing, dated the day it went public.
ACA financials
Revenue growth
+12.2%
XBRL, annual
Net margin
7.2%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$2.7B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM ACA
| FY Dec 2025 | $2.9B |
| FY Dec 2024 | $2.6B |
| FY Dec 2023 | $2.3B |
| FY Dec 2022 | $2.2B |
| FY Dec 2021 | $2.0B |
| Jun 2026 | $658.7M |
| Mar 2026 | $571.7M |
| Dec 2025 | $716.7M |
| Sep 2025 | $797.8M |
| Jun 2025 | $736.9M |
| Mar 2025 | $632.0M |
| Dec 2024 | $666.2M |
| Sep 2024 | $640.4M |
At each fiscal year end
Single quarter
Net margin, TTM
+17.9%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM ACA
| FY Dec 2025 | +7.2% |
| FY Dec 2024 | +3.6% |
| FY Dec 2023 | +6.9% |
| FY Dec 2022 | +11.0% |
| FY Dec 2021 | +3.4% |
| Jun 2026 | +49.9% |
| Mar 2026 | +6.6% |
| Dec 2025 | +7.3% |
| Sep 2025 | +9.2% |
| Jun 2025 | +8.1% |
| Mar 2025 | +3.7% |
| Dec 2024 | -1.2% |
| Sep 2024 | +2.6% |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
capex not filed for the four quarters
Free cash flow, TTM ACA
| FY Dec 2025 | n/a |
| FY Dec 2024 | $312.3M |
| FY Dec 2023 | $57.5M |
| FY Dec 2022 | $36.3M |
| FY Dec 2021 | $81.4M |
| Jun 2026 | -$70.0M |
| Mar 2026 | $28.4M |
| Dec 2025 | $55.8M |
| Sep 2025 | $121.0M |
| Jun 2025 | $33.4M |
| Mar 2025 | -$33.7M |
| Dec 2024 | $194.9M |
| Sep 2024 | $100.6M |
At each fiscal year end
Single quarter
Debt to equity
0.48x
long-term debt only, 2026-06-30; equity 2026-06-30
Debt to equity ACA
| FY Dec 2025 | 0.57x |
| FY Dec 2024 | 0.69x |
| FY Dec 2023 | 0.24x |
| FY Dec 2022 | 0.25x |
| FY Dec 2021 | 0.34x |
| Jun 2026 | 0.48x |
| Mar 2026 | 0.57x |
| Dec 2025 | 0.57x |
| Sep 2025 | 0.61x |
| Jun 2025 | 0.67x |
| Mar 2025 | 0.68x |
| Dec 2024 | 0.69x |
| Sep 2024 | 0.51x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.24x
TTM operating cash flow over long-term debt only, 2026-06-30
Cash flow to debt ACA
| FY Dec 2025 | 0.23x |
| FY Dec 2024 | 0.30x |
| FY Dec 2023 | 0.46x |
| FY Dec 2022 | 0.33x |
| FY Dec 2021 | 0.25x |
| Jun 2026 | 0.24x |
| Mar 2026 | 0.27x |
| Dec 2025 | 0.23x |
| Sep 2025 | 0.30x |
| Jun 2025 | 0.27x |
| Mar 2025 | 0.25x |
| Dec 2024 | 0.30x |
| Sep 2024 | 0.26x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+17.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity ACA
| FY Dec 2025 | +8.2% |
| FY Dec 2024 | +3.9% |
| FY Dec 2023 | +7.0% |
| FY Dec 2022 | +11.9% |
| FY Dec 2021 | +3.6% |
| Jun 2026 | +17.9% |
| Mar 2026 | +8.7% |
| Dec 2025 | +8.2% |
| Sep 2025 | +5.9% |
| Jun 2025 | +3.7% |
| Mar 2025 | +3.2% |
| Dec 2024 | +3.9% |
| Sep 2024 | +5.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+9.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets ACA
| FY Dec 2025 | +4.2% |
| FY Dec 2024 | +2.2% |
| FY Dec 2023 | +4.6% |
| FY Dec 2022 | +7.5% |
| FY Dec 2021 | +2.4% |
| Jun 2026 | +9.5% |
| Mar 2026 | +4.5% |
| Dec 2025 | +4.2% |
| Sep 2025 | +3.2% |
| Jun 2025 | +2.1% |
| Mar 2025 | +1.8% |
| Dec 2024 | +2.2% |
| Sep 2024 | +3.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on invested capital ACA
| FY Dec 2025 | n/a |
| FY Dec 2024 | +3.6% |
| FY Dec 2023 | +6.6% |
| FY Dec 2022 | +10.9% |
| FY Dec 2021 | +3.6% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | +5.8% |
| Jun 2025 | +3.5% |
| Mar 2025 | +3.2% |
| Dec 2024 | +3.6% |
| Sep 2024 | +5.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on capital employed ACA
| FY Dec 2025 | n/a |
| FY Dec 2024 | +5.2% |
| FY Dec 2023 | +7.1% |
| FY Dec 2022 | +12.0% |
| FY Dec 2021 | +4.2% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | +6.6% |
| Jun 2025 | +5.1% |
| Mar 2025 | +4.8% |
| Dec 2024 | +5.2% |
| Sep 2024 | +5.6% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
14.94x
close 2026-10-22 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing ACA
| FY Dec 2025 | 25.08x |
| FY Dec 2024 | 50.65x |
| FY Dec 2023 | 25.35x |
| FY Dec 2022 | 10.78x |
| FY Dec 2021 | 36.85x |
| Jun 2026 | 14.56x |
| Mar 2026 | 23.43x |
| Dec 2025 | 25.08x |
| Sep 2025 | 31.03x |
| Jun 2025 | 46.12x |
| Mar 2025 | 48.50x |
| Dec 2024 | 50.65x |
| Sep 2024 | 36.03x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$8.3B
market value at close 2026-10-22 on 2026-07-15 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
Enterprise value ACA
| FY Dec 2025 | $6.5B |
| FY Dec 2024 | $6.2B |
| FY Dec 2023 | $4.5B |
| FY Dec 2022 | $3.0B |
| FY Dec 2021 | $3.1B |
| Jun 2026 | $8.1B |
| Mar 2026 | $6.6B |
| Dec 2025 | $6.5B |
| Sep 2025 | $5.9B |
| Jun 2025 | $5.7B |
| Mar 2025 | $5.3B |
| Dec 2024 | $6.2B |
| Sep 2024 | $5.1B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
capex not filed for the four quarters
FCF yield ACA
| FY Dec 2025 | n/a |
| FY Dec 2024 | +6.6% |
| FY Dec 2023 | +1.4% |
| FY Dec 2022 | +1.4% |
| FY Dec 2021 | +3.2% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | +6.9% |
| Jun 2025 | +7.0% |
| Mar 2025 | +6.7% |
| Dec 2024 | +6.6% |
| Sep 2024 | +2.6% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.03x
P/E over trailing EPS growth of 431%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing ACA
| FY Dec 2025 | 0.21x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 0.04x |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.03x |
| Mar 2026 | 0.13x |
| Dec 2025 | 0.21x |
| Sep 2025 | 2.09x |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-22. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $2.9B | $2.6B | $2.3B | $2.2B |
| Gross profit | $647.2M | $515.2M | $443.8M | n/a |
| Operating income | $341.9M | $197.6M | $217.3M | $349.0M |
| Net income | $208.4M | $93.7M | $159.2M | $245.8M |
| EPS (diluted) | 4.24 | 1.91 | 3.26 | 5.05 |
| Operating cash flow | $341.1M | $502.0M | $261.0M | $174.3M |
| Cash | $214.6M | $187.3M | $104.8M | $160.4M |
| Long-term debt | $1.5B | $1.7B | $561.9M | $535.9M |
| Buybacks | $0 | $0 | $13.8M | $15.0M |
| Dividends paid | $10.0M | $9.7M | $9.8M | $9.8M |
SEC XBRL, fiscal years, as known on 2026-10-27
ACA Stock Sonar score 5/7 axes
Find similar shapesCompareACA ranks highest on profitability (78th percentile) and growth (71st), and lowest on financial health (45th), among Industrials peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
